The proto-oncogene BCL-6 in normal and malignant B cell development

Hematological Oncology

Volumn 20, Issue 4, 2002, Pages 155-166

  Niu, Huifeng ^a  

^a Columbia University ^*  (United States)

Author keywords

BCL 6; Differentiation; Germinal centre; Lymphoma; Transrepressor

Indexed keywords

IMMUNOGLOBULIN E; PROTEIN BCL 6; ZINC FINGER PROTEIN;

ANTIBODY RESPONSE; B CELL LYMPHOMA; CELL DIFFERENTIATION; CELL INFILTRATION; CHROMOSOME TRANSLOCATION; EOSINOPHIL; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; MEMORY CELL; NONHODGKIN LYMPHOMA; PLASMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; REVIEW; SOMATIC HYPERMUTATION; TH2 CELL; TRANSCRIPTION REGULATION;

ANIMALS; B-LYMPHOCYTES; CD40 LIGAND; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; GENE SILENCING; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, TRANSGENIC; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; TRANSCRIPTION FACTORS;

EID: 0036937410     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.689     Document Type: Review

References (84)

1. Dalla-Favera R, Migliazza A, Chang CC, et al. Molecular pathogenesis of B cell malignancy: the role of BCL-6. Curr Top Microbiol Immunol 1999; 246: 257-263.
2. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824-7827.
3. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991; 88: 9638-9642.
4. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
5. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol 1992; 10: 785-807.
6. Baron BW, Nucifora G, McCabe N, Espinosa RD, Le Beau MM, McKeithan TW. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27; q11) in B-cell lymphomas, Proc Natl Acad Sci USA 1993; 90: 5262-5266.
7. Deweindt C, Kerckaert JP, Tilly H, Quief S, Nguyen VC, Bastard C. Cloning of a breakpoint cluster region at band 3q27 involved in human non-Hodgkin's lymphoma. Genes Chrom Cancer 1993; 8: 149-154.
8. Kerckaert JP, Deweindt C, Tilly H, Quief S, Lecocq G, Bastard C. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nature Genet 1993; 5: 66-70.
9. Miki T, Kawamata N, Hirosawa S, Aoki N. Gene involved in the 3q27 translocation associated with B-cell lymphoma, BCL5, encodes a Kruppel-like zinc-finger protein. Blood 1994; 83: 26-32.
10. Ye BH, Rao PH, Chaganti RS, Dalla-Favera R. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res 1993; 53: 2732-2735.
11. Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262: 747-750.
12. Bastard C, Deweindt C, Kerckaert JP, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994; 83: 2423-2427.
13. Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994; 83: 1757-1759.
14. Otsuki T, Yano T, Clark HM, et al. Analysis of LAZ3 (BCL-6) status in B-cell non-Hodgkin's lymphomas: results of rearrangement and gene expression studies and a mutational analysis of coding region sequences. Blood 1995; 85: 2877-2884.
15. Ohno H and Hayashi T. (Genetic abnormalities in B cell neoplasms: special reference to diffuse large cell lymphoma). Rinsho Ketsueki 1996; 37: 404-407.
16. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2- type inflammation. Nature Genet 1997; 16: 161-170.
17. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997; 276: 589-592.
18. Fukuda T, Yoshida T, Okada S, et al. Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med 1997; 186: 439-448.
19. Dalla-Favera R, Ye BH, Cattoretti G, et al. BCL-6 in diffuse large-cell lymphomas. Important Adv Oncol 1996; 139-148.
20. Ohashi K, Miki T, Hirosawa S, Aoki N. Characterization of the promoter region of human BCL-6 gene. Biochem Biophys Res Commun 1995; 214: 461-467.
21. Deweindt C, Albagli O, Bernardin F, et al. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain. Cell Growth Differ 1995; 6: 1495-1503.
22. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A 1996; 93: 6947-6952.
23. Seyfert VL, Allman D, He Y, Staudt LM. Transcriptional repression by the proto-oncogene BCL-6. Oncogene 1996; 12: 2331-2342.
24. Dhordain P, Albagli O, Lin RJ, et al. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A 1997; 94: 10762-10767.
25. Dhordain P, Lin RJ, Quief S, et al. The LAZ3 (BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase-containing complex to mediate transcriptional repression. Nucl Acids Res 1998; 26: 4645-4651.
26. Kawamata N, Miki T, Ohashi K, et al. Recognition DNA sequence of a novel putative transcription factor, BCL6. Biochem Biophys Res Commun 1994; 204: 366-374.
27. Harris MB, Chang CC, Berton MT, et al. Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: specific regulation of I epsilon transcription and immunoglobulin E switching. Mol Cell Biol 1999; 19: 7264-7275.
28. Rogers SR, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986; 234: 364-368.
29. Moriyama M, Yamochi T, Semba K, Akiyama T, Mori S. BCL-6 is phosphorylated at multiple sites in its serine- and proline- clustered region by mitogen-activated protein kinase (MAPK) in vivo. Oncogene 1997; 14: 2465-2474.
30. Niu H, Ye BH and Dalla-Favera R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev 1998; 12: 1953-1961.
31. Bereshchenko OR, Gu W, Dalla-Favera R. Inhibition of BCL-6 transcriptional repression function by p300-mediated acetylation. Blood 2000; 96: 3028.
32. Matsumoto M, Mariathasan S, Nahm MH, Baranyay F, Peschon JJ, Chaplin DD. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science 1996; 271: 1289-1291.
33. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995; 376: 352-355.
34. Niu H, Pietrafesa R, Cattoretti G, Dalla-Favera R. The BCL-6 proto-oncogene controls apoptosis in B cells. Blood 1999; 94(10): 3065.
35. Reljic R, Wagner SD, Peakman LJ, Fearon DT. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6 (In Process Citation). J Exp Med 2000; 192: 1841-1848.
36. Niu H, Nesic D, Chang CC, Dalla-Favera R. BCL-6 modulates CD40 signaling by silencing NFkB-induced transcription. Blood 2000; 96: 3555.
37. Clark LB, Foy TM, Noelle RJ. CD40 and its ligand. Adv Immunol 1996; 63: 43-78.
38. Lederman S, Cleary AM, Yellin MJ, et al. The central role of the CD40-ligand and CD40 pathway in T-lymphocyte- mediated differentiation of B lymphocytes. Curr Opin Hematol 1996; 3: 77-86.
39. Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 2000; 85(1): 9-21.
40. Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene 2000; 19: 2577-2584.
41. Murphy KM, Ouyang W, Farrar JD, et al. Signaling and transcription in T helper development. Annu Rev Immunol 2000; 18: 451-494.
42. Dent AL, Hu-Li J, Paul WE, Staudt LM. T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc Natl Acad Sci U S A 1998; 95: 13823-13828.
43. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587-596.
44. Kim JI, Ho IC, Grusby MJ, Glimcher LH. The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines. Immunity 1999; 10: 745-751.
45. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15: 707-747.
46. Glimcher LH, Singh H. Transcription factors in lymphocyte development - T and B cells get together. Cell 1999; 96: 13-23.
47. Miaw SC, Choi A, Yu E, Kishikawa H, Ho IC. ROG, repressor of GATA, regulates the expression of cytokine genes. Immunity 2000; 12: 323-333.
48. Toney LM, Cattoretti G, Graf JA, et al. BCL-6 regulates chemokine gene transcription in macrophages. Nature Immunol 2000; 1: 214-220.
49. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000; 13: 199-212.
50. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 1994; 77: 297-306.
51. Evans DE, Munks MW, Purkerson JM, Parker DC. Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40. J Immunol 2000; 164: 688-697.
52. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994; 180: 631-640.
53. Stack RM, Lenschow DJ, Gray GS, Bluestone JA, Fitch FW. IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol 1994; 152: 5723-5733.
54. Allman D, Jain A, Dent A, Maile RR, Selvaggi T, Kehry MR, Staudt LM. BCL-6 expression during B-cell activation. Blood 1996; 87: 5257-5268.
55. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18: 6853-6866.
56. Richards ML, Katz DH. Regulation of the murine Fc epsilon RII (CD23) gene. Functional characterization of an IL-4 enhancer element. J Immunol 1994; 152: 3453-3466.
57. Schaffer A, Cerutti A, Shah S, Zan H, Casali P. The evolutionarily conserved sequence upstream of the human Ig heavy chain S gamma 3 region is an inducible promoter: synergistic activation by CD40 ligand and IL-4 via cooperative NF-kappa B and STAT-6 binding sites. J Immunol 1999; 162: 5327-5336.
58. Delphin S, Stavnezer J. Characterization of an interleukin 4 (IL-4) responsive region in the immunoglobulin heavy chain germline epsilon promoter: regulation by NF-IL-4, a C/EBP family member and NF-kappa B/p50. J Exp Med 1995; 181: 181-192.
59. Iciek LA, Delphin SA, Stavnezer J. CD40 cross-linking induces Ig epsilon germline transcripts in B cells via activation of NF-kappaB: synergy with IL-4 induction. J Immunol 1997; 158: 4769-4779.
60. Messner B, Stutz AM, Albrecht B, Peiritsch S, Woisetschlager M, Cooperation of binding sites for STAT6 and NF kappa B/rel in the IL-4-induced up-regulation of the human IgE germline promoter. J Immunol 1997; 159: 3330-3337.
61. Shen CH, Stavnezer J. Interaction of stat6 and NF-kappaB: direct association and synergistic activation of interleukin-4-induced transcription. Mol Cell Biol 1998; 18: 3395-3404.
62. Offit K, Jhanwar S, Ebrahim SA, Filippa D, Clarkson BD, Chaganti RS. t(3;22)(q27;q11): a novel translocation associated with diffuse non-Hodgkin's lymphoma. Blood 1989; 74: 1876-1879.
63. Bastard C, Tilly H, Lenormand B, et al. Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma. Blood 1992; 79: 2527-2531.
64. Ohno H, Fukuhara S. Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms. Leuk Lymph 1997; 27: 53-63.
65. Ye BH, Chaganti S, Chang CC, et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 1995; 14: 6209-6217.
66. Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5′ noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A 1995; 92: 12520-12524.
67. Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 2000; 95: 651-659.
68. Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci USA 1998; 95: 11816-11821.
69. Shen HM, Peters A, Baron B, Zhu X, Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998; 280: 1750-1752.
70. Pasqualucci L, Neri A, Baldini L, Dalla-Favera R, Migliazza A. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. Cancer Res 2000; 60: 5644-5648.
71. Pasqualucci L, Migliazza A, Ye BH, Cattoretti G, Chaganti RSK, Dalla-Favera R. Transcriptional deregulation of mutated BCL-6 alleles in diffuse large cell lymphomas. Blood 1999; 94: 247.
72. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995; 86: 45-53.
73. Onizuka T, Moriyama M, Yamochi T, et al. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts. Blood 1995; 86: 28-37.
74. Carbone A, Gloghini A, Gaidano G, Dalla-Favera R, Falini B. BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30 + anaplastic large-cell lymphomas. Blood 1997; 90: 2445-2450.
75. Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol 1997; 8(Suppl. 2): 101-104.
76. Kumagai T, Miki T, Kikuchi M, et al. The proto-oncogene Bcl6 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells. Oncogene 1999; 18: 467-475.
77. Yamochi T, Kaneita Y, Akiyama T, Mori S, Moriyama M. Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL- X(L). Oncogene 1999; 18: 487-494.
78. Albagli O, Lantoine D, Quief S, et al. Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci. Oncogene; 1999: 5063-5075.
79. Evan G, Littlewood T. A matter of life and cell death. Science 1998; 281: 1317-1322.
80. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-3162.
81. Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relavance in 71 patients. Ann Oncol 1998; 9: 55-61.
82. Dalla-Favera R, Ye BH, Lo Coco F, et al. Identification of genetic lesions associated with diffuse large-cell lymphoma. Ann Oncol 1994; 5(Suppl. 1): 55-60.
83. Garcia-Sanz R, Vargas Montero M, Gonzalez Diaz M, et al. Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype. Haematologica 1998; 83: 209-216.
84. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large- cell lymphoma (see comments). N Engl J Med 1994; 331: 74-80.